Online citations, reference lists, and bibliographies.
← Back to Search

Novel Norcantharidin-loaded Liver Targeting Chitosan Nanoparticles To Enhance Intestinal Absorption

Yong-yan Bei, X. Chen, Y. Liu, J. Xu, W. Wang, Z. Gu, Kong-lang Xing, Ai-jun Zhu, W. Chen, L. Shi, Q. Wang, X. Zhang, Q. Zhang
Published 2011 · Medicine, Materials Science

Cite This
Download PDF
Analyze on Scholarcy
Share
In this paper, two novel liver-targeting nanoparticles, norcantharidin-loaded chitosan nanoparticles (NCTD-CS-NPs) and norcantharidin -associated galactosylated chitosan nanoparticles (NCTD -GC-NPs), were prepared using ionic cross-linkage. To investigate the intestinal absorption mechanisms of the two preparations, a series of experiments was carried out, including in situ circulation method, in vitro everted gut sacs, and Using chamber perfusion technique. The absorption rate constants (Ka) of NCTD at different segments were duodenum>;jejunum>;ileum>;colon. The concentration had no distinctive effect on absorption kinetics, suggesting that drug absorption is not dose-dependent. The transport of NCTD was found to be inhibited by P-glycoprotein (P-gp) inhibitor, indicating that NCTD might be the substrate of P-gp. The order of the absorption enhancer effects were as follows: low molecular weight chitosan (CS-8kDa) >; high molecular weight chitosan (CS-30KDa) >; Poloxamer >; sodium dodecyl sulfate (SDS) >; Sodium deoxycholate (SDCh). The results indicate that the chitosan nanoparticles can improve intestinal absorption of NCTD.
This paper references
10.1080/17458080903513284
Two modelling data analytical methods applied to optimise the preparation of norcantharidin chitosan nanoparticles
W. Zhang (2010)
10.1615/CRITREVTHERDRUGCARRIERSYST.V21.I5.20
PLGA nanoparticles in drug delivery: the state of the art.
I. Bala (2004)
10.3109/10611869609046260
Drug absorption enhancement, concepts, possibilities, limitations and trends
H. Junginger (1996)
10.1023/A:1013037927882
Comparison of the Lymphatic Transport of Halofantrine Administered in Disperse Systems Containing Three Different Unsaturated Fatty Acids
R. Holm (2004)
Absorption kinetics of ofloxacin in rats in situ
Yang Dong-li (2005)
Using Weibull function to seek dissolution parameters
QZ Li (1991)
10.1248/BPB.18.976
Intestinal absorption of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue. II. In situ and in vitro absorption characteristics of azetirelin from the rat intestine.
I. Sasaki (1995)
10.3109/03639049709148694
In vitro absorption studies and their relevance to absorption from the GI tract
A. Ungell (1997)
10.1021/MP060121R
Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity.
E. Collnot (2007)
10.1016/S0270-9139(03)80220-3
177 Polycationic liposome-mediated extracellular superoxide dismutase gene delivery prevents acute liver injury in mice
J. Wu (2003)
10.1016/S0928-0987(02)00051-9
Lipid-based formulations for intestinal lymphatic delivery.
C. O'Driscoll (2002)
Targeting Drug Delivery System
W. Ying (2002)
10.1097/01.CAD.0000217428.90325.35
Cytotoxicity of cantharidin analogues targeting protein phosphatase 2A
Hong-bo Shan (2006)
10.1023/A:1015882030289
Desolvation Energy: A Major Determinant of Absorption, But Not Clearance, of Peptides in Rats
Michael S. Karls (2004)
Albendazole polybutycyanocrylate nanoparticles-Preparation, pharmaceutical properties and tissue distribution in rats
XN Zhang (2006)
10.1016/j.ejpb.2008.08.015
Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies.
Adwoa O. Nornoo (2009)
10.1016/S0378-5173(01)00777-3
Lactosaminated and intact N-succinyl-chitosans as drug carriers in liver metastasis.
Y. Kato (2001)
10.1080/02652040802365182
Preparation of aminoglycoside-loaded chitosan nanoparticles using dextran sulphate as a counterion
E. Lu (2009)
10.1023/A:1025718513246
Intestinal Lymphatic Transport of Halofantrine Occurs After Oral Administration of a Unit-Dose Lipid-Based Formulation to Fasted Dogs
Shui-Mei Khoo (2004)
10.1016/S1368-8375(01)00129-4
Comparisons of norcantharidin cytotoxic effects on oral cancer cells and normal buccal keratinocytes.
S. Kok (2003)
10.2174/1567201052772834
Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery.
M. J. Cano-Cebrián (2005)
10.1016/S0378-5173(02)00267-3
Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles.
Tanima Banerjee (2002)
10.1016/0378-8741(89)90062-7
Medical uses of mylabris in ancient China and recent studies.
G. Wang (1989)
10.1023/A:1015867608405
The Influence of Peptide Structure on Transport Across Caco-2 Cells. II. Peptide Bond Modification Which Results in Improved Permeability
R. Conradi (2004)
Absorption mechanisms of protein and peptide in oral administration
HY Ji (2003)
10.1002/MED.2610150202
In vitro systems for studying intestinal drug absorption
K. M. Hillgren (1995)
Polycationic liposome-mediated extracellular superoxide dismutase gene delivery prevents acute liver injury in mice
J Wu (2003)
10.1023/A:1016207525186
Comparison of Intestinal Permeabilities Determined in Multiple in Vitro and inSitu Models: Relationship to Absorption in Humans
B. Stewart (2004)
10.1016/j.nano.2009.07.006
Norcantharidin-associated galactosylated chitosan nanoparticles for hepatocyte-targeted delivery.
Q. Wang (2010)
10.1016/J.JFF.2008.09.011
Absorption, Conjugation and Efflux of the Flavonoids, Kaempferol and Galangin, Using the Intestinal CACO-2/TC7 Cell Model.
Robert D. Barrington (2009)
10.1016/S0169-409X(01)00183-1
Intestinal drug efflux: formulation and food effects.
D. Wagner (2001)
10.1016/S0142-9612(01)00399-4
Preparation of alginate/galactosylated chitosan scaffold for hepatocyte attachment.
Taek Woong Chung (2002)
10.1111/j.2042-7158.1991.tb05437.x
The Effect of Site of Administration in the Gastrointestinal Tract on the Absorption of Insulin from Nanocapsules in Diabetic Rats
C. Michel (1991)
LJ.Cytotoxicity of cantharidin analogues targeting protein phosphatase 2A
HB Shan (2006)
Hydrolyze of norcantharidin and subtracting methyla alleviate stimulation of renal system
GS Wang (1983)
10.1016/0145-2126(91)90163-N
Inhibitory effect of norcantharidin on K562 human myeloid leukemia cells in vitro.
S. Yi (1991)
10.1021/JS970300N
Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor.
D. Hauss (1998)
10.1016/J.IJPHARM.2005.01.042
Chitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinate.
Yan Wu (2005)
10.1016/J.JCONREL.2005.03.021
Preparation of nanoparticles composed of poly(gamma-glutamic acid)-poly(lactide) block copolymers and evaluation of their uptake by HepG2 cells.
Hsiang-Fa Liang (2005)
10.1016/S0168-3659(00)00356-4
Biological characteristics of lactosaminated N-succinyl-chitosan as a liver-specific drug carrier in mice.
Y. Kato (2001)
10.1021/JS950285R
Correlation of drug absorption with molecular surface properties.
K. Palm (1996)
Norcantharidin-associated galactosylated chitosan nanoparticles for dual hepatocyte-targeted delivery. Nanomedicine
Q Wang (2010)
Norcantharidin-associated galactosylated chitosan nanoparticles for dual hepatocyte-targeted delivery. Nanomedicine: Nanotechnology, Biology, and Medicine
Q Wang (2010)
10.1016/0959-8049(95)00050-X
Effects of norcantharidin, a protein phosphatase type-2A inhibitor, on the growth of normal and malignant haemopoietic cells.
X. H. Liu (1995)
10.1016/J.MOLMED.2007.07.001
From traditional Chinese medicine to rational cancer therapy.
T. Efferth (2007)
10.1248/BPB.30.1918
In situ intestinal absorption behaviors of tanshinone IIA from its inclusion complex with hydroxypropyl-beta-cyclodextrin.
Wang Ling (2007)
10.1016/S0264-410X(03)00228-7
Chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen, Der p 1 for oral vaccination in mice.
J. L. Chew (2003)
10.1016/J.BCP.2004.12.003
Molecular modes of action of cantharidin in tumor cells.
T. Efferth (2005)
Drug Absorption Enhancement: Concepts, Possibilities, Limitations and Trends
J. Boere (1994)
10.1016/J.EJPS.2006.06.004
Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract.
Y. Masaoka (2006)
10.1016/J.IJPHARM.2006.05.060
A less irritant norcantharidin lipid microspheres: formulation and drug distribution.
Wang Li-xin (2006)
10.1021/JS950267+
Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue.
W. Rubas (1996)
10.1002/JPS.2600800706
In vitro release and intestinal absorption of physostigmine salicylate from submicron emulsions.
A. Rubinstein (1991)



This paper is referenced by
10.3390/ijms17071171
Developments in Methods for Measuring the Intestinal Absorption of Nanoparticle-Bound Drugs
W. Liu (2016)
10.3109/10717544.2013.840692
Primary in vitro and in vivo evaluation of norcantharidin-chitosan/poly (vinyl alcohol) for cancer treatment
Mingna Li (2014)
Design, Synthesis and Biological Evaluation of Small Molecule Inhibitors of the Hedgehog Signaling Pathway
Upasana Banerjee (2014)
10.3892/etm.2018.6416
Preparation and characterization of norcantharidin liposomes modified with stearyl glycyrrhetinate
J. Zhu (2018)
10.2174/1389450115666140309232100
Recent advances in active hepatic targeting drug delivery system.
Y. Wang (2014)
10.1155/2019/7683791
Characterization and Evaluation of a Folic Acid Receptor-Targeted Norcantharidin/Tetrandrine Dual-Drug Loaded Delivery System
Youxiang Xiong (2019)
10.2147/IJN.S96862
Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo
Minchen Liu (2016)
10.1080/15583724.2013.828751
Effect of Physicochemical Properties of Biodegradable Polymers on Nano Drug Delivery
Sonam (2013)
10.2147/IJN.S37455
Polyacrylonitrile nanofibers coated with silver nanoparticles using a modified coaxial electrospinning process
Deng-Guang Yu (2012)
10.1517/17425247.2012.724675
Preclinical evaluations of norcantharidin-loaded intravenous lipid microspheres with low toxicity
X. Lin (2012)
10.1155/2013/838651
Norcantharidin, Derivative of Cantharidin, for Cancer Stem Cells
Chen-Hsi Hsieh (2013)
10.1016/j.bmcl.2015.12.099
Amphiphilic nanoparticles of resveratrol-norcantharidin to enhance the toxicity in zebrafish embryo.
D. Yan (2016)
intravenous lipid microspheres with low toxicity
Xia Lin (2012)
10.1134/S1811238217010088
Bioactive properties of nanochitosan Bombyx mori
R. Yu. Milusheva (2017)
10.7324/japs.2017.70418
Mathematical modeling of drug release from swellable polymeric nanoparticles
S. Azadi (2017)
Semantic Scholar Logo Some data provided by SemanticScholar